Guidance, NICE advice and quality standards In development

Skip to filters Skip to results

Showing 351 to 373 of 373

Sort by

Type: GuidanceRemove Type: Guidance filter

Guidance, NICE advice and quality standards in development
Title	Type	Expected publication date
Pitolisant for treating narcolepsy in children and young people 6 to 17 years ID6353	Technology appraisal guidance	TBC
Pembrolizumab with olaparib for maintenance treatment of non-squamous metastatic non-small-cell lung cancer after pembrolizumab with platinum-based chemotherapy [ID4028]	Technology appraisal guidance	TBC
Drug eluting stents for treating coronary heart disease: late stage assessment	Health technology evaluation	TBC
Hydromethylthionine mesylate for treating mild cognitive impairment or mild or moderate dementia caused by Alzheimer's disease ID6343	Technology appraisal guidance	TBC
Palopegteriparatide for treating chronic hypoparathyroidism ID6380	Technology appraisal guidance	TBC
Topical Antimicrobial dressings for wound care: Late stage assessment	Health technology evaluation	TBC
Nivolumab with ipilimumab for untreated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency [ID1136]	Technology appraisal guidance	TBC
Idebenone for treating visual impairment in Leber's hereditary optic neuropathy in people 12 years and over [ID547]	Technology appraisal guidance	TBC
Guselkumab for previously treated moderately to severely active Crohn's disease ID6238	Technology appraisal guidance	TBC
Guselkumab for treating moderately to severely active ulcerative colitis ID6237	Technology appraisal guidance	TBC
Nemolizumab for treating moderate to severe atopic dermatitis in people aged 12 and over or prurigo nodularis in adults ID6221	Technology appraisal guidance	TBC
Artificial intelligence (AI) technologies for assessing skin lesions referred on the urgent suspected cancer pathway	Health technology evaluation	TBC
Atezolizumab for untreated advanced or recurrent non-small cell lung cancer when platinum-doublet chemotherapy is unsuitable [ID6218]	Technology appraisal guidance	TBC
Trastuzumab deruxtecan for treating HER2-low metastatic or unresectable breast cancer after chemotherapy [ID3935]	Technology appraisal guidance	TBC
Dupilumab for treating moderate to severe chronic obstructive pulmonary disease ID6235	Technology appraisal guidance	TBC
Nivolumab with ipilimumab for untreated unresectable stage 3 non-small-cell lung cancer [ID6248]	Technology appraisal guidance	TBC
Topical rapamycin for treating facial angiofibromas associated with tuberous sclerosis complex in people 6 years and over [ID6391]	Technology appraisal guidance	TBC
Marstacimab for treating severe haemophilia A or severe haemophilia B in people 12 years and over [ID6342]	Technology appraisal guidance	TBC
Olaparib with cediranib for treating platinum-resistant recurrent ovarian cancer after 1 or 2 therapies [ID6129]	Technology appraisal guidance	TBC
Efgartigimod for treating generalised myasthenia gravis [ID4003]	Technology appraisal guidance	TBC
Ruxolitinib for treating moderate to severe chronic graft-versus-host disease after an allogeneic stem cell transplant in people 28 days to 17 years [ID6427]	Technology appraisal guidance	TBC
Asthma: diagnosis, monitoring and chronic asthma management	NICE guideline	TBC
Pembrolizumab with platinum-based chemotherapy then pembrolizumab maintenance for treating advanced or recurrent endometrial cancer ID6381	Technology appraisal guidance	TBC

Results per page

10
25
50
All